You are here

  • Home
  • Archive
  • Volume 70, Issue 6
  • Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial

Article info

Article menu
Chronic obstructive pulmonary disease
Original article
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial

Authors

  1. Correspondence to Professor Peter Frith, Respiratory Medicine, Southern Adelaide Local Health Network, Repatriation General Hospital, 216 Daws Rd, Daw Park, SA 5041, Australia; Peter.frith{at}health.sa.gov.au
View Full Text

Citation

Frith PA, Thompson PJ, Ratnavadivel R, et al
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial
Thorax 2015;70:519-527.

Publication history

  • Received December 9, 2014
  • Revised March 16, 2015
  • Accepted March 19, 2015
  • First published April 3, 2015.
Online issue publication 
September 01, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/